See the DrugPatentWatch profile for xarelto
Xarelto (rivaroxaban) has not been taken off the market. It remains an approved anticoagulant medication used to prevent blood clots in various conditions, including atrial fibrillation, deep vein thrombosis, and pulmonary embolism [1].
Why Might Someone Think Xarelto Was Removed?
Concerns about Xarelto have primarily stemmed from a significant number of lawsuits alleging serious bleeding events and other adverse effects. These lawsuits have been consolidated in multidistrict litigation (MDL) [2]. While these legal challenges are substantial, they do not equate to the drug being removed from the market.
What Kind of Lawsuits Are Facing Xarelto?
Lawsuits against Xarelto's manufacturers, Bayer and Johnson & Johnson's Janssen Pharmaceuticals, generally claim that the drug's risks were not adequately disclosed to patients and healthcare providers. Allegations include that the drug was more dangerous than alternative treatments and that its manufacturers failed to warn about severe bleeding complications [2].
How is Xarelto Currently Regulated?
Xarelto is approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1]. Regulatory approval signifies that the drug has met established safety and efficacy standards. Ongoing monitoring and post-market surveillance by these agencies continue to assess its safety profile.
What Are the Approved Uses for Xarelto?
Xarelto is prescribed for several indications:
* To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1].
* To treat deep vein thrombosis (DVT) and reduce the risk of recurrence [1].
* To treat pulmonary embolism (PE) and reduce the risk of recurrence [1].
* To reduce the risk of DVT and PE in patients who have undergone hip or knee replacement surgery [1].
* To reduce the risk of major cardiovascular events in patients with coronary artery disease or peripheral artery disease [1].
What Are the Alternatives to Xarelto?
Other anticoagulants are available, including warfarin (a vitamin K antagonist) and other direct oral anticoagulants (DOACs) such as apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Lixiana/Savaysa) [3]. The choice of anticoagulant depends on individual patient factors, including medical history, other medications, and physician recommendation.
When Does Xarelto's Patent Protection End?
Patent protection for Xarelto has been a complex issue, with various patents covering the drug and its uses [4]. Information on specific patent expiry dates and potential challenges can be found through resources like DrugPatentWatch.com [4]. Patent expiry is a crucial factor for the potential introduction of generic versions of the medication.
Sources:
[1] https://www.rxlist.com/consumer_xarelto/drugs/drug-item.htm
[2] https://www.drugwatch.com/xarelto/lawsuit/
[3] https://www.heart.org/en/health-topics/atrial-fibrillation/treatment-of-atrial-fibrillation/anticoagulant-therapy-blood-thinners
[4] https://drugpatentwatch.com/